Drug Guide

Generic Name

Icosapent Ethyl

Brand Names Vascepa

Classification

Therapeutic: Lipid-Lowering Agent, Omega-3 Fatty Acid Derivative

Pharmacological: Eicosapentaenoic Acid Ethyl Ester

FDA Approved Indications

  • Reduction of cardiovascular risk in adults withEditor's note: Original user query- At risk of cardiovascular disease, with elevated triglycerides (≥150 mg/dL) despite management of other risk factors.

Mechanism of Action

Icosapent ethyl reduces hepatic triglyceride synthesis and enhances triglyceride clearance, primarily through anti-inflammatory, anti-thrombotic, and membrane-stabilizing effects of eicosapentaenoic acid, decreasing plasma triglyceride levels.

Dosage and Administration

Adult: 2 grams twice daily, with food.

Pediatric: Not approved for pediatric use.

Geriatric: No specific dose adjustments; monitor renal/hepatic function as appropriate.

Renal Impairment: No specific adjustment needed; monitor levels.

Hepatic Impairment: Use with caution; no specific guidelines, monitor liver function.

Pharmacokinetics

Absorption: Well absorbed when taken with food.

Distribution: Widely distributed; high plasma protein binding.

Metabolism: Minimal hepatic metabolism; primarily excreted unchanged.

Excretion: Excreted mainly in feces; minor renal excretion.

Half Life: Approximately 89 hours.

Contraindications

  • Hypersensitivity to fish or shellfish.
  • Use with caution in patients on anticoagulants or antiplatelet agents due to increased bleeding risk.

Precautions

  • Monitor bleeding time.
  • Use with caution in patients with bleeding disorders or those taking medications affecting coagulation.
  • Pregnancy Category: Not established; consult healthcare provider.

Adverse Reactions - Common

  • Arthralgia (Less than 5%)
  • Pain in extremities (Less than 5%)
  • Back pain (Less than 5%)
  • Muscle pain (myalgia) (Less than 5%)

Adverse Reactions - Serious

  • Bleeding or abnormal bleeding (Rare)
  • Atrial fibrillation and/flutter (Rare)

Drug-Drug Interactions

  • Anticoagulants (e.g., warfarin, apixaban) — increased bleeding risk.
  • Antiplatelet agents — increased bleeding risk.

Drug-Food Interactions

  • No significant food interactions identified.

Drug-Herb Interactions

  • Caution with concomitant herbal supplements affecting coagulation (e.g., ginseng, garlic, ginkgo).

Nursing Implications

Assessment: Monitor lipid profile, liver function tests, and signs of bleeding.

Diagnoses:

  • Risk for bleeding.
  • Imbalanced nutrition: less than body requirements (if gastrointestinal side effects occur).

Implementation: Advise taking with food, monitor for signs of bleeding, and assess response to therapy.

Evaluation: Aim for reduction in triglyceride levels and stabilization of cardiovascular risk.

Patient/Family Teaching

  • Take medication exactly as prescribed, with food.
  • Report any signs of bleeding (e.g., unusual bruising, bleeding gums).
  • Maintain a healthy diet and lifestyle to support cardiovascular health.
  • Inform healthcare providers about all medications and supplements.

Special Considerations

Black Box Warnings:

  • Increase in bleeding risk.

Genetic Factors: No specific genetic considerations identified.

Lab Test Interference: May affect coagulation tests; interpret results accordingly.

Overdose Management

Signs/Symptoms: Excessive bleeding, gastrointestinal bleeding.

Treatment: Supportive care; discontinue medication; consider consultation with poison control for further guidance.

Storage and Handling

Storage: Store at room temperature, 20–25°C (68–77°F).

Stability: Stable under recommended storage conditions for the duration of the shelf life.

This guide is for educational purposes only and is not intended for clinical use.